Inject Today
Primary RecommendationFaricimab 6mg intravitreal injection, right eye. Treat-and-extend protocol — maintain 6-week interval pending response.
Recurrence Risk Prediction
Probability of fluid recurrence if injection deferred
AI Explainability — Why Inject?
6 contributing factors · OPHTAI validatedDAS of 78 is in the high-activity range (>65). This is the single strongest predictor for injection need. The score incorporates fluid volume, BCVA change, and OCT biomarker severity.
This recommendation was generated by the RetinoFlow OCT Foundation Model (v2.4) and independently validated by the OPHTAI API platform (concordance: 94%). All decisions remain at the discretion of the treating clinician. For CE-marking and SaMD compliance, all AI outputs are logged with full audit trail.
Alternative Pathways
Extension to 8 weeks is not recommended given active SRF/IRF and DAS 78. High probability of further VA decline (estimated −6 to −10 letters over 8 weeks without treatment).
Not RecommendedObservation without injection carries 97% recurrence risk within 4 weeks per longitudinal model. Not clinically appropriate given current biomarker profile.
Not RecommendedAgent switch may be considered if faricimab response remains inadequate after 2 further injections at 6-week intervals. Current evidence supports continuing faricimab unless tachyphylaxis confirmed.
ConditionalShort deferral acceptable if patient unable to attend today and INR check pending (Warfarin). Reschedule within 48 hours. Risk of significant additional fluid accumulation is low over this period.
ConditionalPhysician Decision
Injection Parameters
Audit Trail
15 May 2026AI recommendation generated
21:11RetinoFlow AI v2.4
OPHTAI validation completed
21:11OPHTAI API · 94% concordance
OCT scan analysed
21:09OCT Foundation Model v2.4
OCT scan acquired
20:44Heidelberg Spectralis · Technician: R. Patel
Patient checked in
09:32Reception · Clinic visit #18
Full audit log exportable for MDR/SaMD compliance reporting.